While low-dose aspirin may help prevent heart disease, a randomized, placebo-controlled study of almost 40,000 women finds that alternate day use of 100 mg aspirin for an average of 10 years does not lower the risk of total, breast, or colorectal cancer.
While low-dose aspirin may help prevent heart disease, a randomized, placebo-controlled study of almost 40,000 women finds that alternate day use of 100 mg aspirin for an average of 10 years does not lower the risk of total, breast, or colorectal cancer.
The study, which is the longest of any trial on this matter to be completed to date and which is part of the Women's Health Study, did show a trend toward reduction in the risk of lung cancer that was significant for lung cancer deaths, but the findings require confirmation.
Whether higher doses of aspirin confer protective benefits, as some previous studies have indicated, cannot be ruled out.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More